Business
CalciMedica Announces Publication in the American Journal of Nephrology Discussing Design and Rationale of Phase 2 KOURAGE Trial of Auxora™ in AKI with Respiratory Failure
CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced a publication in the American Journal of Nephrology (AJN) highlighting the design and rationale of the Company's Phase 2 KOURAGE trial of lead candidate Auxora™ in acute kidney injury (AKI) with respiratory failure.
About this update from Calcimedica, Inc.
[{"type":"text","content":"Publication includes previously announced preclinical data of Auxora™ in acute kidney injury (AKI) models as well as a post-hoc analysis of patients in the Phase 2 CARDEA trial of Auxora in severe COVID-19 pneumonia who had AKI with respiratory failure at enrollment","length":266,"tagName":"p","attribs":{}},{"type":"text","content":"LA JOLLA, Calif., June 25, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced a publication in the American Journal of Nephrology (AJN) highlighting the design and rationale of the Company's Phase 2 KOURAGE trial of lead candidate Auxora™ in acute kidney injury (AKI) with respiratory failure.","length":572,"tagName":"p"},{"type":"image","alt":"CalciMedica Logo (PRNewsfoto/CalciMedica, Inc.)","displaySize":"","headline":null,"caption":"CalciMedica Logo (PRNewsfoto/CalciMedica, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":78,"url":"https://media.zenfs.com/en/prnewswire.com/2555f332bbc6176084dcbe2b673b28ae"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/OrsqdcERGNiUdevuO33D2A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTEzNztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/2555f332bbc6176084dcbe2b673b28ae","width":400,"height":78}},"href":"https://mma.prnewswire.com/media/685404/calcimedica_v3.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The manuscript, entitled, "Inhibition of Calcium Release-Activated Calcium (CRAC) Channels to Treat Acute Kidney Injury: Design and Rationale of the KOURAGE Study," was co-authored by Lakhmir Chawla, M.D., Clinical Professor of Medicine at University of California San Diego, Chief Medical Officer at ExThera Medical, and Chair of the KOURAGE Steering Committee; Sudarshan Hebbar, M.D., Chief Medical Officer of CalciMedica; Glenn Chertow, M.D., Norman S. Coplon/ Satellite Healthcare Professor of Medicine, Professor of Epidemiology and Population Health and Health Policy at Stanford Medicine, and Member of the KOURAGE Steering Committee; and other CalciMedica collaborators.","length":72...